Rising Malaysian Medical Costs and Insurance Coverage: A Deep Dive
KUALA LUMPUR, March 16 — Medical claim payouts in Malaysia have significantly increased in recent years, prompting discussions about the adequacy of current insurance coverage and the sustainability of healthcare financing. Prudential Assurance Malaysia Berhad (PAMB) reported a doubling of claim payouts from RM1 billion in 2022 to over RM2 billion in 2024, with a notable RM1.04 million claim paid out in 2025 for breast cancer treatment. This surge in costs and claims is driving a re-evaluation of insurance plans and the potential need for higher coverage limits.
The Increasing Complexity and Cost of Cancer Treatment
PAMB highlighted the increasing complexity of cancer care as a key driver of rising medical expenses. A recent case involved a senior policyholder requiring multiple surgeries, a prolonged intensive care unit (ICU) stay, and advanced cancer therapies, resulting in a claim exceeding RM1 million. Manisha Keyal, PAMB’s chief health officer, emphasized that these trends reflect advancements in oncology and Malaysia’s expanding access to specialized medical capabilities. Prudential’s PRUCancer X plan aims to address these costs by providing a lump sum benefit upon cancer diagnosis.
Are Current Insurance Limits Adequate?
PAMB argues that traditional annual insurance limits, such as RM50,000 or RM100,000 common in 2013, are no longer sufficient to cover modern healthcare needs, particularly for serious illnesses requiring prolonged or complex treatment. The company stresses that higher annual limits are designed to provide adequate financial protection against escalating medical costs.
This perspective contrasts with Bank Negara Malaysia’s (BNM) proposal for a base medical and health insurance/takaful (MHIT) product, which suggests an annual limit of RM100,000 for those under 60 and RM150,000 for those over 60 could cover 99% of treatment episodes. PRUSignature Care, underwritten by Prudential Assurance Malaysia Berhad, is one example of a plan distributed by Standard Chartered Bank Malaysia Berhad.
Claims Experience and Premium Pricing
PAMB maintains that premiums are determined through actuarial pricing based on factors like claims experience, medical inflation, healthcare utilization patterns, and the policyholder’s age and health status. The company refuted claims that annual limits are merely a marketing tactic, stating they exist to ensure customers have adequate financial protection. PAMB reported a medical claim approval rate exceeding 90%, above the industry average, indicating a commitment to paying legitimate claims.
Trends in Medical Claims
Data from PAMB reveals that policyholders aged 60 and above recorded the highest medical claim payouts, with women accounting for 52% of all medical claims in 2024. The most common medical conditions claimed included heart disease, breast cancer, cataract, pneumonia, and gastritis, with payouts ranging from RM64 million to RM120 million. The increase in hospital utilization, reflected in higher admission volumes and claims, contributed to the 100% rise in PAMB’s medical claim payouts between 2022 and 2024.
Transparency and Responsible Sales Practices
PAMB emphasizes the importance of transparency in communicating policy terms, including exclusions and pre-existing condition clauses, to customers during the point of sale. All newly appointed Prudential agents are required to complete mandatory training and pass an assessment to ensure they can effectively explain coverage details and identify potential risks. Agents are also provided with tools, such as a medical disclosure guide, to support clear communication with customers.
The Future of Medical Insurance in Malaysia
The increasing costs of healthcare and the evolving needs of patients are driving ongoing discussions about the future of medical insurance in Malaysia. PAMB continues to engage with policymakers and industry stakeholders to support efforts aimed at ensuring access to quality care while maintaining a sustainable healthcare system. The debate surrounding the Base MHIT framework and the adequacy of coverage limits will likely continue as the industry seeks to balance affordability, accessibility, and comprehensive protection for Malaysians.